Oral implants in patients receiving bisphosphonates: A review and update

Medicina Oral, Patologia Oral y Cirugia Bucal

Volumn 13, Issue 12, 2008, Pages

  Serra, María Paz Mínguez ^a   Llorca, César Salort ^b   Donat, Francisco Javier Silvestre ^a,c  

^a HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^b HOSPITAL MÚTUA DE TERRASSA   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Bisphosphonates; Implants; Oral surgery; Osteonecrosis; Osteoporosis

Indexed keywords

ACREL; ADROVANCE; ALENDROCARE; ALENDRONIC ACID; ALENDRONIC ACID PLUS COLECALCIFEROL; BIFOAL; BISPHOSPHONIC ACID DERIVATIVE; BONDENZA; CALCITONIN; CALCIUM; CLODRONIC ACID; CORTICOSTEROID; ETIDRONIC ACID; HYDROXYAPATITE; IBANDRONIC ACID; LINOTEN; OSTEUM; PAMIDRONIC ACID; PAMIFOS; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; TAMOXIFEN; TILUDRONIC ACID; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID;

BONE REMODELING; CLINICAL TRIAL; DISEASE PREDISPOSITION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; HORMONE SUBSTITUTION; HUMAN; JAW OSTEONECROSIS; NONHUMAN; ORAL SURGERY; OSTEOPOROSIS; PERIODONTAL DISEASE; PERIODONTITIS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; TOOTH IMPLANTATION; TREATMENT DURATION;

DENTAL IMPLANTS; DIPHOSPHONATES; HUMANS; RISK FACTORS;

EID: 59949104618     PISSN: 16984447     EISSN: 16986946     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Hwang D, Wang HL. Medical contraindications to implant therapy: part I: absolute contraindications. Implant Dent. 2006 Dec; 15(4):353-60.
2. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998 Feb; 19(1):80-100.
3. Fleisch H. Development of bisphosphonates. Breast Cancer Res. 2002 ;4(1):30-4.
4. Ponte-Fernández N, Estefanía-Fresco R, Aguirre-Urizar JM. Bisphosphonates an oral pathology I. General and preventive aspects. Med Oral Patol Oral Cir Bucal. 2006 Aug 1; 11(6):E396-400.
5. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonates-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005 Nov; 63(11):1567-75.
6. Estefanía-Fresco R, Ponte-Fernández N, Aguirre-Urizar JM. Bisphosphonates and oral pathology II. Osteonecrosis of the jaws: review of the literature before 2005. Med Oral Patol Oral Cir Bucal. 2006 Nov 1; 11(6):456-61.
7. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol. 2005 Dec 1; 23(34):8580-7.
8. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of in-crease risk after treatment with zoledronic acid. Haematologica. 2006 Jul;91(7):968-71.
9. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005 Jul 7;353(1):99-102.
10. Ruggiero SL, Mehrotra B, Rosenber TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004 May;62(5):527-34.
11. Scully C, Madrid C, Bagan J. Dental endosseous implants in patients on bisphosphonate therapy. Implant Dent. 2006 Sep;15(3):212-8.
12. Grant BT, Amenedo C, Freeman K, Kraut RA. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J Oral Maxillofac Surg. 2008 Feb ;66(2)223-30.
13. Cosman F, Borges JL, Curiel MD. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies. Clin Ther. 2007 Jun;29(6):1116-27.
14. Jeffcoat M. The assocation between osteoporosis and oral bone loss. J Periodontol 2005. Nov;76(11 Suppl):2125-32.
15. Rosen CJ, Hochberg M, Bonnick SL, McClung M, Miller P, Broy S et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res. 2005 Jan;20(1):141-51.
16. Jeffcoat MK. Safety of oral bisphosphonates: controlled studies on alveolar bone. Int J Oral Maxillofac Implants. 2006 May-Jun;21(3):349-53.
17. Chacon GE, Stine EA, Larsen PE, Beck FM, McGlumphy EA. Effect of alendronate on endosseous implant integration: an in vivo study in rabbits. J Oral Maxillofac Surg. 2006 Jul;64(7):1005-9.
18. Friberg B, Ekestubbe A, Mellström D, Sennerby L. Brånemark implants and osteoporosis: A clinical exploratory study. Clin Implant Dent Relat Res. 2001;3(1):50-6.
19. Minsk L, Polson AM. Dental implant outcomes in post-menopausal women undergoing hormone replacement. Compend Contin Educ Dent. 1998 Sep;19(9):859-62.
20. August M, Chung K, Chang Y, Glowacki J. Influence of estrogen status on endosseus implant osseointegration. J Oral Maxillofac Surg. 2001 Nov;59(11):1285-9.
21. Weinreb M, Quartuccio H, Seedor JG, Aufdemorte TB, Brunsvold M, Chaves E et al. Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys. J Periodontol Res. 1994 Jan;29(1):35-40.
22. Brunsvold MA, Chaves ES, Kornman KS, Aufdemorte TB, Wood R. Effects of a bisphosphonate on experimental periodontitis in monkeys. J Periodontol. 1992 Oct;63(10):825-30.
23. Takaishi Y, Ikeo T, Miki T, Nishizawa Y, Morii H. Suppression of alveolar bone resorption by etidronate treatment for periodontal disease: 4 to 5-year follow-up of four patients. J Int Med Res. 2003 Nov-Dec;31(6):575-84.
24. Takaishi Y. Treatment of periodontal disease, prevention and bisphosphonate. Clin Calcium. 2003 Feb;13(2):173-6.
25. El-Shinnawi UM, El-Tantawy SI. The effect of alendronate sodium on alveolar bone loss in periodontitis (clinical trial). J Int Acad Periodontol. 2003 Jan;5(1):5-10.
26. Kajiwara H, Yamaza T, Yoshinari M, Goto T, Iyama S, Atsuta I et al. The bisphosphonate pamidronate on the surface of titanium stimulates bone formation around tibial implants in rats. Biomaterials. 2005 Feb;26(6):581-7.
27. Altundal H, Güvener O. The effect of alendronate on resorption of the alveolar bone following tooth extraction. Int J Oral Maxillofac Surg. 2004 Apr;33(3):286-93.
28. Denissen H, Montanari C, Martinetti R, van Lingen A, van den Ho-off A. Alveolar bone response to submerged bisphosphonate-complexed hydroxyapatite implants. J Periodontol. 2000 Feb;71(2):279-86.
29. Rocha ML, Malacara JM, Sánchez-Marin FJ, Vazquez de la Torre CJ, Fajardo ME. Effect of alendronate on periodontal disease in postmenopausal women: A randomized placebo-controlled trial. J Periodontol. 2004 Dec;75(12):1579-85.
30. Rizzoli R, Greenspan SL, Bone G 3rd, Schnitzer TJ, Watts NB, Adami S, et al. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.J Bone Miner Res. 2002 Nov;17(11):1988-96.
31. Bagán J, Blade J, Cozar JM, Constela M, García Sanz R, Gómez Veiga F et al. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal. 2007 Aug 1;12(4):336-40.
32. Wang HL, Weber D, McCauley LK. Effect of long-term oral bisphosphonates on implant wound healing: literature review and a case report. J Periodontol. 2007 mar;78(3):373-6.
33. Berardi D, Carlesi T, Rossi F, Calderini M, Volpi R, Perfetti G. Potential applications of bisphosphonates in dental surgical implants. Int J Immunopathol Pharmacol. 2007 Jul-Sep;20(3):455-65.